Here are the most promising energy tech startups in the market today. Natalie Harms/InnovationMap

This week, 39 energy startup companies from all over the world pitched in Houston — and nine were recognized as being the most promising of the batch.

The Rice Alliance for Technology and Entrepreneurship returned its Offshore Technology Conference pitch event to its in-person capacity and host the annual event at the Ion Houston for the first time. The event featured three-minute pitches from the companies, and a select group of corporate and venture investors decided on the top nine to honor.

"We asked investors and corporates to look at the companies here today and help us determine the companies most promising — based on those that have an innovative technology that is solving a large problem, has customers willing to pay for it, and has the right team to build and grow their company," Brad Burke, managing director of the Rice Alliance says to the crowd at the event on May 3.

Here's which energy tech companies stood out to investors.

EarthEn

EarthEn, a Chandler, Arizona-based company, is a grid-scale energy storage solution. The technology can provide short-term — 6 to 8 hours — and long-term — over 100 hours — storage. The EarthEn pods provide a cheaper alternative and are built using 3D printing.

Echogen Power Systems

Based in Akron, Ohio, Echogen Power Systems has created a technology that captures heat that would otherwise be lost and converts it to a useable power source. The solution allows for any customer that operates at significant levels of heat to have a cost-effective energy option.

FuelX Innovation

Based in Aiken, South Carolina, FuelX Innovation is manufacturing solid-state hydrogen products and power systems, impacting mobile hydrogen fuel cell-powered applications. The company is focused on producing the lowest cost Alane, or aluminum hydride, for the fuel cell.

Lillianah Technologies

Lillianah Technologies, based in the Houston area in Spring, uses algae to remove carbon dioxide from the atmosphere. The company sells carbon offsets to corporations.

oPRO.ai

oPRO.ai — which is based in Los Altos, California — is providing its customers with deep learning optimization software for process and responsible operations for oil and gas, petrochemical, chemicals, and metal industries.

Proteum Energy

Phoenix, Arizona-based Proteum Energy provides its customers low-cost, clean hydrogen by reforming renewable ethanol into renewable hydrogen.

Sync Power Solutions

Embracing a clean sheet approach, Sync Power Solutions, based in Abilene, Texas, created a solution involving a redesign of electric motors and generators to increase energy efficiency, save on costs, and more.

Utility Global

Houston-based Utility Global is using high temperature electrolysis without the use of electricity to produce hydrogen from waste gases.

ZL Innovations

Based in Portland, Oregon, ZL Innovations is focused on eliminating greenhouse gas emissions from failed industrial valves. The company's solution is a magnetic actuation assembly that can be better sealed to prevent emissions.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”